"At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients" - September 20, 2023

Witnesses:
John Czwartacki, Founder, Survivors for Solutions
-----
Dr. Steve Potts, Ph.D., MBA, Chair, Drug Development Council, International Cancer Advocacy Network
-----
John Crowley, Executive Chairman, Amicus Therapeutics, Inc.
-----
Dr. Aaron S. Kesselheim, M.D., J.D., M.P.H., Professor of Medicine at Harvard Medical School, Director, Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital